Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® Business Wire (press release) Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ... |
